An overview of multiple myeloma in dogs and cats - Veterinary Medicine
Medicine Center
DVM Veterinary Medicine Featuring Information from:


An overview of multiple myeloma in dogs and cats
These plasma cell tumors originate in the bone marrow and can cause a variety of effects, from hemorrhaging to spinal cord compression.



1. Matus RE, Leifer CE, MacEwen EG, et al. Prognostic factors for multiple myeloma in the dog. J Am Vet Med Assoc 1986;188(11):1288-1292.

2. Vail DM. Plasma cell neoplasms. In: Withrow SJ, Vail DM, eds. Withrow & MacEwen's small animal clinical oncology. St. Louis, Mo: Saunders Elsevier, 2007;769-784.

3. Cowgill ES, Neel JA, Ruslander D. Light-chain myeloma in a dog. J Vet Intern Med 2004;18(1):119-121.

4. Patel RT, Caceres A, French AF, et al. Multiple myeloma in 16 cats: a retrospective study. Vet Clin Pathol 2005;34(4):341-352.

5. Hanna F. Multiple myelomas in cats. J Feline Med Surg 2005;7(5):275-287.

6. Mellor PJ, Haugland S, Smith KC, et al. Histopathologic, immunohistochemical, and cytologic analysis of feline myeloma-related disorders: further evidence for primary extramedullary development in the cat. Vet Pathol 2008;45(2):159-173.

7. Mellor PJ, Haugland S, Murphy S, et al. Myeloma-related disorders in cats commonly present as extramedullary neoplasms in contrast to myeloma in human patients: 24 cases with clinical follow-up. J Vet Intern Med 2006;20(6):1376-1383.

8. Rosenblatt J, Hall CA. Plasma-cell dyscrasia following prolonged stimulation of reticuloendothelial system. Lancet 1970;1(7641):301-302.

9. Imahori S, Moore GE. Multiple myeloma and prolonged stimulation of reticuloendothelial system. N Y State J Med 1972;72(12):1625-1628.

10. Penny R, Hughes S. Repeated stimulation of the reticuloendothelial system and the development of plasma-cell dyscrasias. Lancet 1970;1(7637):77-78.

11. Speer SA, Semenza JC, Kurosaki T, et al. Risk factors for acute myeloid leukemia and multiple myeloma: a combination of GIS and case-control studies. J Environ Health 2002;64(7):9-16; quiz 35-6.

12. Tonon, G. Molecular pathogenesis of multiple myeloma. Hematol Oncol Clin North Am 2007;21(6):985-1006, vii.

13. Bergsagel PL, Kuehl WM, Zhan F, et al. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 2005;106(1):296-303.

14. Cangul IT, Wijnen M, Van Garderen E, et al. Clinico-pathological aspects of canine cutaneous and mucocutaneous plasmacytomas. J Vet Med A Physiol Pathol Clin Med 2002;49(6):307-312.

15. Peterson EN, Meininger AC. Immunoglobulin A and immunoglobulin G biclonal gammopathy in a dog with multiple myeloma. J Am Anim Hosp Assoc 1997;33(1):45-47.

16. Yamada O, Tamura K, Yagihara H, et al. Light-chain multiple myeloma in a cat. J Vet Diagn Invest 2007;19(4):443-447.

17. Rusbridge C, Wheeler SJ, Lamb CR, et al. Vertebral plasma cell tumors in 8 dogs. J Vet Intern Med 1999;13(2):126-133.

18. Edwards CM, Zhuang J, Mundy GR. The pathogenesis of the bone disease of multiple myeloma. Bone 2008;42(6):1007-1013.

19. Heath DJ, Vanderkerken K, Cheng X, et al. An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma. Cancer Res 2007;67(1):202-208.

20. Dimopoulos M, Terpos E, Comenzo RL, et al. International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma. Leukemia 2009 May 7. [Epub ahead of print]

21. Glaspy JA. Hemostatic abnormalities in multiple myeloma and related disorders. Hematol Oncol Clin North Am 1992;6(6):1301-1314.

22. Webb J, Chary P, Northrup N, et al. Erythrophagocytic multiple myeloma in a cat. Vet Clin Pathol 2008;37(3):302-307.

23. Yearley JH, Stanton C, Olivry T, et al. Phagocytic plasmacytoma in a dog. Vet Clin Pathol 2007;36(3):293-296.

24. Hom BL, Olsen CL. Phagocytic plasma cells in patients with multiple myeloma. Am J Clin Pathol 1984;81(5):689-690.

25. Dimopoulos MA, Kastritis E, Rosinol L, et al. Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia 2008;22(8):1485-1493.

26. Sheafor SE, Gamblin RM, Couto CG. Hypercalcemia in two cats with multiple myeloma. J Am Anim Hosp Assoc 1996;32(6):503-508.

27. Hendrix DV, Gelatt KN, Smith PJ, et al. Ophthalmic disease as the presenting complaint in five dogs with multiple myeloma. J Am Anim Hosp Assoc 1998;34(2):121-128.

28. Giraudel JM, Pages JP, Guelfi JF. Monoclonal gammopathies in the dog: a retrospective study of 18 cases (1986-1999) and literature review. J Am Anim Hosp Assoc 2002;38(2):135-147.

29. Font A, Closa JM, Mascort J. Monoclonal gammopathy in a dog with visceral leishmaniasis. J Vet Intern Med 1994;8(3):233-235.

30. Burkhard MJ, Meyer DJ, Rosychuk RA, et al. Monoclonal gammopathy in a dog with chronic pyoderma. J Vet Intern Med 1995;9(5):357-360.

31. Olteanu H, Wang HY, Chen W, et al. Immunophenotypic studies of monoclonal gammopathy of undetermined significance. BMC Clin Pathol 2008;8:13.

32. Leigh BR, Kurtts TA, Mack CF, et al. Radiation therapy for the palliation of multiple myeloma. Int J Radiat Oncol Biol Phys 1993;25(5):801-804.

33. Mayer MN, Kerr ME, Grier CK, et al. Immunoglobulin A multiple myeloma with cutaneous involvement in a dog. Can Vet J 2008;49(7):694-702.

34. Hostutler RA, Chew DJ, Jaeger JQ, et al. Uses and effectiveness of pamidronate disodium for treatment of dogs and cats with hypercalcemia. J Vet Intern Med 2005;19(1):29-33.

35. Fan TM, de Lorimier LP, Charney SC, et al. Evaluation of intravenous pamidronate administration in 33 cancer-bearing dogs with primary or secondary bone involvement. J Vet Intern Med 2005;19(1):74-80.

36. Terpos E, Sezer O, Croucher PI, et al. The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. Ann Oncol 2009 May 22. [Epub ahead of print]

37. de Lorimier LP, Fan TM. Understanding and recognizing cancer pain in dogs and cats. Vet Med 2005;100(5):352-362.

38. de Lorimier LP, Fan TM. Treating cancer pain in dogs and cats. Vet Med 2005;100(5):364-379.

39. Zarkovic M, Kwaan HC. Correction of hyperviscosity by apheresis. Semin Thromb Hemost 2003;29(5):535-542.

40. Fan TM, Kitchell BE, Dhaliwal RS, et al. Hematological toxicity and therapeutic efficacy of lomustine in 20 tumor-bearing cats: critical assessment of a practical dosing regimen. J Am Anim Hosp Assoc 2002;38(4):357-363.

41. Field-Smith, A, Morgan GJ, Davies FE. Bortezomib (Velcadetrade mark) in the treatment of multiple myeloma. Ther Clin Risk Manag 2006;2(3):271-279.

42. Orlowski RZ, Kuhn DJ. Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res 2008;14(6):1649-1657.

43. Hicks LK, Haynes AE, Reece DE, et al. A meta-analysis and systematic review of thalidomide for patients with previously untreated multiple myeloma. Cancer Treat Rev 2008;34(5):442-452.

44. London CA, Hannah AL, Zadovoskaya R, et al. Phase 1 dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies. Clin Cancer Res 2003;9(7):2755-2768.


Click here